drugset / Trial / NCT05912049
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW3811 | Monoclonal antibody | — | Intravenous |